A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis

Pulmonary arterial hypertension (PAH) is a rare complication of ANCA-associated vasculitis (AAV). We report a 37-year-old man with PAH complicated by both AAV and SSc who presented with dyspnea, cardiac enlargement, positive myeloperoxidase (MPO)-ANCA, anti-centromere antibodies, proteinuria, and ur...

Full description

Saved in:
Bibliographic Details
Published inImmunological Medicine Vol. 44; no. 4; pp. 263 - 269
Main Authors Yoshifuji, Hajime, Kagebayashi, Sumika, Kinoshita, Hideyuki, Fujii, Takao, Okano, Yoshiaki, Katsushima, Masao, Mimori, Tsuneyo
Format Journal Article
LanguageEnglish
Published England Informa UK Limited 01.12.2021
Taylor & Francis Group
Subjects
Online AccessGet full text
ISSN2578-5826
2578-5826
DOI10.1080/25785826.2021.1874137

Cover

More Information
Summary:Pulmonary arterial hypertension (PAH) is a rare complication of ANCA-associated vasculitis (AAV). We report a 37-year-old man with PAH complicated by both AAV and SSc who presented with dyspnea, cardiac enlargement, positive myeloperoxidase (MPO)-ANCA, anti-centromere antibodies, proteinuria, and urinary casts. Elevated pulmonary arterial pressure (58/22/34 mmHg) and low PAWP (2 mmHg) were confirmed by right heart catheterization. Treatment with glucocorticoids (GC) decreased urinary protein and serum MPO-ANCA; however, PAH did not respond to GC. Therefore, a combination of beraprost, bosentan, and tadalafil was needed. The differences in responses to GC suggest that the pathophysiology of nephropathy is different from that of PAH. We considered that nephropathy was associated with AAV but that PAH was associated with SSc in the present case. We discuss the pathophysiology and treatment response of PAH complicated by AAV, referring to nine past cases.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2578-5826
2578-5826
DOI:10.1080/25785826.2021.1874137